Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [3]
- Other assay [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-56754 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- FAM83B Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: ALGDRFEGYD NPENLKANAL YTHSRLRSSL VFKPTLPEQK EVNSCTTGSS NSTIIGSQGS ETPKEVPDTP TNVQHLTDKP LPESIPKLPL QS
- Concentration
- 0.6 mg/mL
Submitted references FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.
He S, Wang W, Wan Z, Shen H, Zhao Y, You Z, Liu J, Zhu L
Oncogenesis 2021 Jan 9;10(1):6
Oncogenesis 2021 Jan 9;10(1):6
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of FAM83B in human skin and liver tissues using FAM83B Polyclonal Antibody (Product # PA5-56754). Corresponding FAM83B RNA-seq data are presented for the same tissues.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of FAM83B in human skin using FAM83B Polyclonal Antibody (Product # PA5-56754) shows high expression.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of FAM83B in human liver using FAM83B Polyclonal Antibody (Product # PA5-56754) shows low expression as expected.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 Ovarian cancer patients with low FAM83B expression had poor clinic outcome. a Kaplan-Meier plots indicate the progression-free survival, overall survival and post progression survival for ovarian cancer patients categorized by FAM83B expression. P -value is determined by log-rank test. b GSEA analysis of the relationship between FAM83B level and cisplatin resistance. c Q-PCR and western blot analysis of FAM83B expression in ovarian cancer tissues with cisplatin resistance and cisplatin response. * P < 0.05. Error bars in panels are defined as s.d.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Patients with low FAM83B expression had poor clinic outcome. a Representative IHC pictures for FAM83B expression in ovarian cancer tissues. b Kaplan-Meier plots indicate the overall survival and relapse-free survival for ovarian cancer patients categorized by FAM83B expression. p -value is determined by log-rank test.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 FAM83B inhibits cisplatin resistance in vitro. a Q-PCR and western blot analysis of FAM83B expression after infecting virus carried FAM83B overexpression vector and FAM83B shRNA vector. b Cell viability analysis of the effect of FAM83B overexpression or knockdown on cisplatin resistance. c Annexin/PI apoptosis analysis of the effect of FAM83B overexpression or knockdown on cisplatin resistance. d TUNEL analysis of the effect of FAM83B overexpression or knockdown on cisplatin resistance. * p < 0.05. Error bars in panels are defined as s.d.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 7 FAM83B levels were negatively correlated with Wnt pathway activity. a Q-PCR analysis of BCL2, XIAP and CCND1 in ovarian cancer tissues. b western blot analysis of FAM83B and nuclear beta-catenin expression in ovarian cancer tissues. statistical analysis of the relationship between FAM83 expression and nuclear beta-catenin expression in ovarian cancer tissues. Error bars in panels are defined as s.d.
